News

Oculis Reveals Promising Phase 2 ACUITY Results at ECTRIMS

Oculis Reveals Promising Phase 2 ACUITY Results at ECTRIMS

Oculis Announces Phase 2 ACUITY Trial Results at ECTRIMS

Oculis Holding AG (Nasdaq: OCS / XICE: OCS) proudly declared the upcoming presentation of the positive results from the Phase 2 ACUITY trial examining Privosegtor (OCS-05) in patients with acute optic neuritis. This crucial presentation will take place during the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress.

Highlights from the ACUITY Trial Results

During the ECTRIMS Congress, one of the central presentations will be titled "Reduction in Retinal Ganglion Cell Loss and Improved Low Contrast Visual Acuity with Privosegtor in Acute Optic Neuritis: Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial." It will be presented by Dr. Céline Louapre from Pitié-Salpêtrière Hospital.

Dr. Louapre is set to present these compelling findings at a session focused on Late Breaking Abstracts, scheduled for the morning of September 24, 2025, at 08:30 CET.

Significant Comments from Oculis Leadership

Dr. Riad Sherif, the Chief Executive Officer of Oculis, expressed enthusiasm about collaborating with Pitié-Salpêtrière Hospital, emphasizing the significance of this trial for patients suffering from acute optic neuritis. He stated, "Topline results revealed clinically meaningful vision improvements, showcasing advancements in retinal structure preservation alongside a favorable safety profile. These findings propose a wide applicability of Privosegtor across multiple neuro-ophthalmic and neurological disorders. We're excited to engage with the MS community as we progress in our studies."

Insights from Dr. Céline Louapre

Dr. Louapre remarked about the privilege of presenting at ECTRIMS, highlighting the promising neuroprotective effects witnessed in the trial. She noted significant enhancements in low contrast visual acuity, reflecting the potential of Privosegtor to positively impact patients experiencing acute relapses of multiple sclerosis.

Understanding Privosegtor (OCS-05)

Privosegtor is an innovative peptoid small molecule candidate aimed at becoming a leading neuroprotective therapy for optic neuritis and related neuro-ophthalmic conditions. The encouraging results from the Phase 2 ACUITY trial demonstrate Privosegtor's capability for neuroprotection through anatomical preservation of the retina coupled with substantial improvements in visual function in individuals suffering from acute optic neuritis.

Promising Animal Model Results

Early studies involving animal models of neuroinflammation and neurodegeneration have mirrored human results. Animals treated with Privosegtor exhibited remarkable preservation of retinal ganglion cells, as well as enhancements in mobility. Price-sensitive behavior is also notable, as the ongoing research could lead to significant developments within neurology and ophthalmology.

About Acute Optic Neuritis

Acute optic neuritis is an infrequent yet serious condition resulting from inflammation of the optic nerve, often leading to permanent visual loss. This condition predominantly affects adults between 20 and 40 years of age, with a higher prevalence in females. Though remyelination can occur once inflammation subsides, the damage to neurons can be irreversible, underscoring the critical need for effective neuroprotective treatments.

The Need for Neuroprotective Therapies

Currently, there are no approved neuroprotective therapies specifically for acute optic neuritis, making the development of Privosegtor paramount. The ongoing trials and research efforts by Oculis aim to meet this crucial medical need.

Oculis: Innovating Healthcare Solutions

Oculis operates as a distinguished global biopharmaceutical entity dedicated to innovating treatment solutions for ophthalmic and neuro-ophthalmic conditions. Their product pipeline showcases potential breakthrough candidates like OCS-01 and OCS-02, focusing on non-invasive treatments for diabetic macular edema and personalized medicine strategies for dry eye disease, respectively. Headquartered in Switzerland, Oculis is managed by a proficient team and backed by leading healthcare investors.

Frequently Asked Questions

What are the Phase 2 ACUITY trial results about?

They showcase the efficacy of Privosegtor in reducing retinal ganglion cell loss and improving visual function in patients with acute optic neuritis.

What is Privosegtor (OCS-05)?

Privosegtor is a neuroprotective drug candidate currently undergoing trials for treatment in acute optic neuritis and other neuro-ophthalmic diseases.

Who will present the trial results at ECTRIMS?

The results will be presented by Dr. Céline Louapre from Pitié-Salpêtrière Hospital.

What is acute optic neuritis?

It is a condition caused by inflammation of the optic nerve, often presenting as the initial symptom of multiple sclerosis.

Is Privosegtor approved for use?

No, it is still an investigational drug in Phase 2 and not yet approved for commercial distribution in any country.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Home Energy Tips: Embrace the Electrical Panel Shift

Updated Category News Views 13

Why Electrical Panels Matter More Than Ever Back in the day, electrical panels weren't exactly the star of the homeowner show. But times have changed, and those previously mundane boxes of switches and wires now demand a spotlight. Shifts in modern lifestyles have catapulted electrical systems into the spotlight, making upgrades a pressing conversation topic for savvy...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 75

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
ISC2 Launches AI Security Academy for Cyber Pros

Updated Category News Views 147

AI-Driven Threats Demand Expert Attention Every corner of the tech world has been blabbering about AI, but when it comes to cybersecurity, it's a whole different beast entirely. ISC2—a nonprofit that I like to think of as the cyber wizards’ guild—just threw a lifeline to cybersecurity folks who are swimming in the deep end of AI. With their shiny new AI Security...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 106

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 170

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Dr. Obeng Joins WellcomeMD with Special Offer for Patients

Updated Category News Views 23

New Beginnings in Concierge Medicine In late October, WellcomeMD opened its doors to Dr. Paa-Kofi Obeng—an arrival greeted with considerable anticipation in Richmond's medical scene. This isn't just any run-of-the-mill staff addition; Dr. Obeng brings with him over a decade of experience from places like the Veterans Administration Medical Center. He's armed with a...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 111

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
The Melt Grabs Top Spot in Burger Ratings War

Updated Category News Views 40

Burger Battle: The Melt Claims Victory When you're in the cutthroat world of fast-casual dining, grabbing the top spot on any list is no small potatoes. The Melt did just that, snatching the title of America’s Highest-Rated Burger Spot. Based on an in-depth analysis of Google and Yelp reviews, folks have spoken, loud and clear, over the past two years. It's a world...

Continue Reading
Cargo Drones to Skyrocket with $9.14B Value by 2031

Updated Category News Views 87

Riding the Drone Wave I tell you what, folks, the whole business of cargo drones is getting frickin' interesting. These flying gizmos, once dismissed as science fiction, are now barging their way into logistics discussions like an uninvited guest who's too worthwhile to ignore. MarketsandMarkets™ reckons this market's about to smash through the $9 billion ceiling by...

Continue Reading
BETR's Legal Tangle: A Deeper Dive into Investor Turmoil

Updated Category News Views 52

BETR's Shaky Ground: When Promises Fall Short In the rough-and-tumble world of finance, there's little room for empty promises. Better Home & Finance Holding Company (NASDAQ: BETR) might have to learn that the hard way. Investors who snagged shares between March 13 and August 6, 2026, are now clutching their heads as they watch their investments nosedive. When companies...

Continue Reading

Top 5 Most Recently Viewed Articles

boberdoo Launches Dynamic Consent for Enhanced User Privacy

Updated Category News Views 92

boberdoo's Innovative Approach to One-to-One Consent boberdoo is making waves with its Dynamic Consent solution, a vital tool for businesses looking to comply with the FCC's one-to-one consent regulation. This live solution has been available since May 2024 and is designed to enhance transparency in lead generation by allowing consumers to have a voice in which companies...

Continue Reading
Understanding the Recent Private Student Loan Trends and Insights

Updated Category News Views 254

Overview of Recent Trends in Private Student Loans In the recent semi-annual Private Student Loan Report released by Enterval Analytics, insights into the current status of private student loans reveal a stable repayment landscape. Since Enterval focuses on the private student loan market, their findings shed light on how borrowers are adapting their financial strategies...

Continue Reading
Kyocera Unveils Exclusive Knife Set Celebrating 40 Years of Innovation

Updated Category News Views 62

Kyocera celebrated four decades of pushing boundaries in ceramic cutlery, revealing an exclusive two-piece knife set designed for both chefs and home cooks. The knives—a 4.5-inch Utility and a 5.5-inch Santoku—come dressed in vibrant Aegean Blue or Botanical Green and carry a price tag of $85. This limited-edition release is set to hit select retailers by late fall...

Continue Reading
PTC Plans Conference Call for Upcoming Fiscal Q1 Results

Updated Category News Views 145

PTC to Hold Fiscal Q1 Conference Call Boston, January 2026 — PTC (NASDAQ: PTC) is gearing up to unveil its financial performance for the first quarter of fiscal year 2026 on February 4. Investors and interested parties are invited to join a conference call and webcast at 5 PM Eastern Time, right after the stock market closes. This event will provide valuable insights...

Continue Reading
Moke America Unveils Enhanced Electric Street Vehicle for All

Updated Category News Views 282

Introducing the New Electric Street-Legal Moke Moke America, the beloved electric vehicle manufacturer, has taken a bold step forward with the launch of its latest street-legal Moke. Previously classified as a Low Speed Vehicle, this newly upgraded Moke can now reach an impressive top speed of 45 MPH, transforming the driving experience into something truly exhilarating....

Continue Reading